{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:13:41Z","timestamp":1794896021411,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["2019E520201"],"award-info":[{"award-number":["2019E520201"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The emergence of drug-resistant tuberculosis (DR-TB) is a major healthcare concern worldwide. Here, we analyzed age-related trends in DR-TB rates in South Korea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Drug susceptibility test results were collected from patients with culture-confirmed TB between 2015 and 2018 from eight university-affiliated hospitals. Patients were divided into three subgroups: younger (15\u201334\u2009years), middle (35\u201359\u2009years), and older (\u226560\u2009years) to compare drug-resistance patterns. To evaluate trends in age-stratified drug-resistance, chi-square test for linear trends was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among enrolled native patients aged \u226515\u2009years, 4.1% (179\/4417), 1.2% (53\/4417) and 7.2% (316\/4417) were multidrug-resistant TB (MDR-TB), rifampicin-mono-resistant TB (RR-TB), and isoniazid-mono-resistant TB (Hr-TB), respectively. Proportions of Hr-TB cases were 5.4% (40\/734), 7.2% (114\/1593), and 7.8% (162\/2090) in the younger, middle and older age groups, respectively. MDR\/RR-TB case rates decreased significantly with age from 8.6% (63\/734) in younger age group to 3.3% (68\/2090) in older age group. Fluoroquinolone resistance was highest among second-line drugs, and there were no differences in resistance to fluoroquinolones and second-line injectable drugs among the three age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The number of MDR\/RR-TB cases was highest in young patients. Effective public health interventions should include increased focus on rifampicin resistance in young patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05157-6","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T07:03:07Z","timestamp":1592895787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study"],"prefix":"10.1186","volume":"20","author":[{"given":"Eung Gu","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsoo","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Kyu","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Haak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4433-231X","authenticated-orcid":false,"given":"Ju Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"5157_CR1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","volume":"394","author":"C Lange","year":"2019","unstructured":"Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR. Management of drug-resistant tuberculosis. Lancet. 2019;394:953\u201366.","journal-title":"Lancet"},{"key":"5157_CR2","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","volume":"385","author":"M Uplekar","year":"2015","unstructured":"Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. Lancet. 2015;385:1799\u2013801.","journal-title":"Lancet"},{"key":"5157_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S1473-3099(17)30246-3","volume":"17","author":"A Mariandyshev","year":"2017","unstructured":"Mariandyshev A, Eliseev P. Drug-resistant tuberculosis threatens WHO's end-TB strategy. Lancet Infect Dis. 2017;17:674\u20135.","journal-title":"Lancet Infect Dis"},{"key":"5157_CR4","first-page":"571","volume":"11","author":"GH Bai","year":"2007","unstructured":"Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL. Trend of anti-tuberculosis drug resistance in Korea, 1994\u20132004. Int J Tuberc Lung Dis. 2007;11:571\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5157_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3904\/kjim.2018.052","volume":"34","author":"H Kim","year":"2019","unstructured":"Kim H, Mok JH, Kang B, Lee T, Lee HK, Jang HJ, et al. Trend of multidrug and fluoroquinolone resistance in mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study. Korean J Intern Med. 2019;34:344\u201352.","journal-title":"Korean J Intern Med"},{"key":"5157_CR6","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3201\/eid2111.141894","volume":"21","author":"JH Kim","year":"2015","unstructured":"Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis. 2015;21:1913\u201320.","journal-title":"Emerg Infect Dis"},{"key":"5157_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jctube.2018.04.006","volume":"11","author":"U Go","year":"2018","unstructured":"Go U, Park M, Kim UN, Lee S, Han S, Lee J, et al. Tuberculosis prevention and care in Korea: evolution of policy and practice. J Clin Tuberc Other Mycobact Dis. 2018;11:28\u201336.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"5157_CR8","unstructured":"Piubello A, A\u00eft-Khaled N, Caminero JA, Chiang C-Y, Dlodlo RA, Fujiwara PI, et al. Field guide for the management of drug-resistant tuberculosis. Int Union Against Tubercul Lung Dis. 2018. https:\/\/www.theunion.org\/what-we-do\/publications\/technical\/english\/TheUnion_DR-TB-Guide.pdf."},{"key":"5157_CR9","volume-title":"Companion handbook to the who guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Companion handbook to the who guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014."},{"key":"5157_CR10","unstructured":"The Korean Academy of Tuberculosis and Respiratory Disease.\u00a0Korean Guidelines for Tuberculosis, Third Edition. The Korean Academy of Tuberculosis and Respiratory Disease. 2017. https:\/\/www.lungkorea.org\/bbs\/index.html?code=guide&page=2."},{"key":"5157_CR11","volume-title":"Revised definitions and reporting framework for tuberculosis","author":"WHO","year":"2013","unstructured":"WHO. Revised definitions and reporting framework for tuberculosis. Geneva: World Health Organization; 2013."},{"key":"5157_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4103\/0019-5154.185700","volume":"61","author":"A Hazra","year":"2016","unstructured":"Hazra A, Gogtay N. Biostatistics series module 4: comparing groups - categorical variables. Indian J Dermatol. 2016;61:385\u201392.","journal-title":"Indian J Dermatol"},{"key":"5157_CR13","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Global tuberculosis report 2019."},{"key":"5157_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5588\/ijtld.16.0716","volume":"21","author":"HR Stagg","year":"2017","unstructured":"Stagg HR, Lipman MC, McHugh TD, Jenkins HE. Isoniazid-resistant tuberculosis: a cause for concern? Int J Tuberc Lung Dis. 2017;21:129\u201339.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5157_CR15","doi-asserted-by":"publisher","first-page":"e89822","DOI":"10.1371\/journal.pone.0089822","volume":"9","author":"SC Suen","year":"2014","unstructured":"Suen SC, Bendavid E, Goldhaber-Fiebert JD. Disease control implications of India's changing multi-drug resistant tuberculosis epidemic. PLoS One. 2014;9:e89822.","journal-title":"PLoS One"},{"key":"5157_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(15)00458-0","volume":"3","author":"EA Kendall","year":"2015","unstructured":"Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med. 2015;3:963\u201372.","journal-title":"Lancet Respir Med"},{"key":"5157_CR17","volume-title":"Consolidated guidelines on drug-resistant tuberculosis treatment","author":"WHO","year":"2019","unstructured":"WHO. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019."},{"key":"5157_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4046\/trd.2017.80.2.143","volume":"80","author":"BH Kang","year":"2017","unstructured":"Kang BH, Jo KW, Shim TS. Current status of Fluoroquinolone use for treatment of tuberculosis in a tertiary Care Hospital in Korea. Tuberc Respir Dis (Seoul). 2017;80:143\u201352.","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"5157_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S1473-3099(18)30073-2","volume":"18","author":"M Zignol","year":"2018","unstructured":"Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, et al. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infect Dis. 2018;18:675\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5157_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2015.01.006","volume":"32","author":"K Jabeen","year":"2015","unstructured":"Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Int J Infect Dis. 2015;32:118\u201323.","journal-title":"Int J Infect Dis"},{"key":"5157_CR21","doi-asserted-by":"publisher","first-page":"e2017056","DOI":"10.4178\/epih.e2017056","volume":"39","author":"J Heo","year":"2017","unstructured":"Heo J, Jeon SY, Oh CM, Hwang J, Oh J, Cho Y. The unrealized potential: cohort effects and age-period-cohort analysis. Epidemiol Health. 2017;39:e2017056.","journal-title":"Epidemiol Health"},{"key":"5157_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tube.2018.06.003","volume":"111","author":"K Kim","year":"2018","unstructured":"Kim K, Yang JS, Choi H, Kim H, Park SH, Jeon SM, et al. A molecular epidemiological analysis of tuberculosis trends in South Korea. Tuberculosis (Edinb). 2018;111:127\u201334.","journal-title":"Tuberculosis (Edinb)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05157-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05157-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05157-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T19:35:32Z","timestamp":1624390532000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05157-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5157"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05157-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-17875\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The Institutional Review Board of the Catholic Medical Center, the Catholic University of Korea approved the study protocol (XC19REDE0040) and waived the need for informed consent because no patients were at risk.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"446"}}